Preventing follicular lymphoma progression with precision therapy
Official title: Preventing follicular lymphoma progression and transformation through precision therapy
Funded at New York University School of Medicine · NIH-11504820 · Data updated 2026-11-12
This grant tests a targeted approach to stop follicular lymphoma from getting worse or turning into a more aggressive cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | June 1, 2022 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $492,396 |
| NIH project number | 7R01CA270245-05 |
| Project ID | NIH-11504820 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with follicular lymphoma or related B-cell lymphomas who may benefit from precision therapies targeting BCL2 or EZH2 pathways.
✕Less likely to help
Patients without follicular lymphoma or those not eligible for the specific precision therapies studied may not benefit.
What this research studies
Follicular lymphoma is a slow-growing blood cancer that can persist and relapse over time. The project aims to understand how these cancer cells survive and how to prevent disease progression using personalized treatment strategies. Researchers will study the genetic and immune interactions in the tumor to design rational therapies that block progression and transformation. The work involves analyses of how BCL2 and EZH2-related changes influence the tumor environment and response to therapy. If successful, the findings could guide more effective, tailored treatments for patients with FL.
Why it matters
Potential benefit: If successful, patients with follicular lymphoma could experience slower disease progression and fewer transformations to aggressive disease.
How similar studies have gone: Prior research has shown that targeting BCL2 and EZH2 pathways can influence lymphoma cell survival and immune interactions, supporting potential benefit of this approach.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Beguelin, Wendy — New York University School of Medicine
- Study coordinator: Beguelin, Wendy
Related research
Other NIH-funded projects on the same topics.
-
Follicular Lymphoma: Better Diagnosis and Personalized Risk in B-Cell Lymphomas
This NIH grant aims to improve how doctors diagnose and predict outcomes for people with follicular lymphoma by finding reliable biomarkers to guide treatment decisions.
-
IRF4's role in shaping the tumor environment in follicular lymphoma
This grant aims to understand how a molecule called IRF4 changes the tumor surroundings in follicular lymphoma to identify potential new ways to help patients.
-
Gene test to predict early treatment failure in follicular lymphoma
A lab test that reads genes in lymphoma biopsy tissue to spot people with follicular lymphoma who are likely to have their disease return within two years after standard immunochemotherapy.
-
How mutant STAT6 affects follicular lymphoma
This project looks at how a gene change called STAT6 affects follicular lymphoma to help find better treatments for people with this cancer.
-
Preventing the progression of follicular lymphoma with targeted therapy
This study is looking at how slow-growing follicular lymphomas can change into more aggressive forms, and it's working to find personalized treatments that target the specific factors that help these tumors survive, so we can help patients live better and longer.
-
Developing a test to predict early treatment failure in follicular lymphoma
This study is looking to help doctors better predict which patients with follicular lymphoma might not respond well to standard treatment, using a special test on tissue samples to find important genetic clues, so they can create more personalized treatment plans for you.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.